ArticleOpen forum infectious diseases2019
Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven Model.
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Impact of a pharmacist-led hepatitis C clinic on hepatitis A and B vaccination rates and treatment outcomes: A retrospective cohort study.Journal of managed care & specialty pharmacy · 2026Article
- Exploring the harm reduction paradigm: the role of Board-Certified Psychiatric Pharmacists.The mental health clinician · 2024Article
- Impact of a Pharmacist-Led HCV Treatment Program at a Federally Qualified Health Center.Pharmacy (Basel, Switzerland) · 2024Article
- A cross-sectional survey of viral hepatitis education within pharmacy curricula in the United States.International journal of clinical pharmacy · 2024Article
- 'Canadian liver journal · 2024Article
- Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs.Drug and alcohol dependence reports · 2024Article
- Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- The role of community pharmacies in the HIV and HCV care continuum.Exploratory research in clinical and social pharmacy · 2023Article
- Impact of an interdisciplinary patient care model and routine screening on clinical outcomes in patients with hepatitis C.Innovations in pharmacy · 2023Article
- Barriers and facilitators to implementing a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) to treat hepatitis C among people who inject drugs.The International journal on drug policy · 2023Article
- Interprofessional Collaboration Between a Clinical Pharmacist and Specialty Physicians to Treat Hepatitis C in an Interdisciplinary Medical Practice Setting.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2022Article
- Patient Access to Hepatitis C Treatment After Incorporation of Pharmacists in a Hepatology Clinic.Hospital pharmacy · 2022Article
- 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.Addiction science & clinical practice · 2021Article
- Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access.The mental health clinician · 2021Article
- Improving Medication-Related Outcomes in Chronic Liver Disease.Hepatology communications · 2020Review
- Can community pharmacists treat hepatitis C virus?The lancet. Gastroenterology & hepatology · 2020Article
- Accelerating the elimination of hepatitis C in Kuwait: An expert opinion.World journal of gastroenterology · 2020Review
- Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy).Medicina (Kaunas, Lithuania) · 2020Article
- Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy.Frontiers in pharmacology · 2020Article
- Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment Access.Public health reports (Washington, D.C. : 1974)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe US National Viral Hepatitis Action Plan depends on additional providers to expand hepatitis C virus (HCV) treatment capacity in order to achieve elimination goals. Clinical pharmacists manage treatment and medication within interdisciplinary teams. The study's objective was to determine sustained virologic response (SVR) rates for clinical pharmacist-delivered HCV therapy in an open medical system.
methodsInvestigators conducted a multicenter retrospective cohort study of patients initiating direct-acting antivirals from January 1, 2014, through March 12, 2018. Data included demographics, comorbidities, treatment, and clinical outcomes. The primary outcome of SVR was determined for patients initiating (intent-to-treat) and those who completed (per-protocol) treatment. Chi-square tests were conducted to identify associations between SVR and adverse reactions, drug-drug interactions, and adherence.
resultsA total of 1253 patients initiated treatment; 95 were lost to follow-up, and 24 discontinued therapy. SVR rates were 95.1% (1079/1134) per protocol and 86.1% (1079/1253) intent to treat. The mean age (SD) was 57.4 (10.1) years, the mean body mass index (SD) was 28.7 (6.2) kg/m2, 63.9% were male, 53.7% were black, 40.3% were cirrhotic, 88.4% were genotype 1, and 81.6% were treatment-naïve. Patients missing ≥1 dose had an SVR of 74.9%; full adherence yielded 90% (P < .0001).
conclusionsHCV treatment by clinical pharmacists in an open medical system resulted in high SVR rates comparable to real-world studies with specialists and nonspecialists. These findings demonstrate the success of a clinical pharmacist-delivered method for HCV treatment expansion and elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.